PT831911E - Terapeutica de combinacao de espironolactona e antagonista da angiotensina ii para o tratamento de insuficiencia cardiaca congestiva - Google Patents
Terapeutica de combinacao de espironolactona e antagonista da angiotensina ii para o tratamento de insuficiencia cardiaca congestivaInfo
- Publication number
- PT831911E PT831911E PT96919173T PT96919173T PT831911E PT 831911 E PT831911 E PT 831911E PT 96919173 T PT96919173 T PT 96919173T PT 96919173 T PT96919173 T PT 96919173T PT 831911 E PT831911 E PT 831911E
- Authority
- PT
- Portugal
- Prior art keywords
- angiotensin
- receptor antagonist
- spironolactone
- treatment
- preferred
- Prior art date
Links
- 239000002333 angiotensin II receptor antagonist Substances 0.000 title abstract 4
- 229960002256 spironolactone Drugs 0.000 title abstract 3
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 title abstract 3
- 206010019280 Heart failures Diseases 0.000 title abstract 2
- 229940123413 Angiotensin II antagonist Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 abstract 3
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 abstract 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 3
- 229940044551 receptor antagonist Drugs 0.000 abstract 3
- 239000002464 receptor antagonist Substances 0.000 abstract 3
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 abstract 2
- 238000002648 combination therapy Methods 0.000 abstract 2
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 abstract 1
- -1 3,5-dibutyl-1H-1,2,4-triazol-1-yl Chemical group 0.000 abstract 1
- 206010003445 Ascites Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48608995A | 1995-06-07 | 1995-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT831911E true PT831911E (pt) | 2002-09-30 |
Family
ID=23930539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT96919173T PT831911E (pt) | 1995-06-07 | 1996-06-05 | Terapeutica de combinacao de espironolactona e antagonista da angiotensina ii para o tratamento de insuficiencia cardiaca congestiva |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20040102423A1 (pt) |
| EP (1) | EP0831911B1 (pt) |
| JP (1) | JPH11509838A (pt) |
| KR (1) | KR19990022723A (pt) |
| CN (1) | CN1192696A (pt) |
| AT (1) | ATE216261T1 (pt) |
| AU (1) | AU6158096A (pt) |
| BR (1) | BR9608505A (pt) |
| CA (1) | CA2224222A1 (pt) |
| CZ (1) | CZ291268B6 (pt) |
| DE (1) | DE69620756T2 (pt) |
| DK (1) | DK0831911T3 (pt) |
| ES (1) | ES2175098T3 (pt) |
| IL (1) | IL122246A (pt) |
| PT (1) | PT831911E (pt) |
| WO (1) | WO1996040258A2 (pt) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6306826B1 (en) | 1997-06-04 | 2001-10-23 | The Regents Of The University Of California | Treatment of heart failure with growth hormone |
| US6211217B1 (en) | 1999-03-16 | 2001-04-03 | Novartis Ag | Method for reducing pericardial fibrosis and adhesion formation |
| CN1268331C (zh) | 1999-08-30 | 2006-08-09 | 萨诺费－阿文蒂斯德国有限公司 | 肾素－血管紧张素系统抑制剂在制备预防心血管疾病的药物中的用途 |
| HUP0301057A3 (en) * | 2000-02-18 | 2004-01-28 | Takeda Pharmaceutical | Angiotenzin ii antagonist heterocyclic compound an their use for preparation of tnf-alpha inhibitors |
| JP5082033B2 (ja) | 2001-12-21 | 2012-11-28 | エグゼリクシス パテント カンパニー エルエルシー | Ｌｘｒのモジュレーター |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| DE10335027A1 (de) * | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
| CA2520763A1 (en) | 2003-04-03 | 2004-10-21 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
| CA2559665A1 (en) | 2004-03-16 | 2005-09-29 | The Regents Of The University Of California | Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids |
| ZA200703613B (en) | 2004-10-20 | 2009-05-27 | Univ California | Improved inhibitors for the soluble epoxide hydrolase |
| EP1831225A2 (en) * | 2004-11-19 | 2007-09-12 | The Regents of the University of California | Anti-inflammatory pyrazolopyrimidines |
| CA2909277A1 (en) | 2006-04-04 | 2007-10-11 | Kevan M. Shokat | Kinase antagonists |
| WO2008021666A2 (en) * | 2006-08-18 | 2008-02-21 | Morton Grove Pharmaceuticals, Inc. | Stable liquid levetiracetam compositions and methods |
| GB2467670B (en) | 2007-10-04 | 2012-08-01 | Intellikine Inc | Chemical entities and therapeutic uses thereof |
| SG10201605472WA (en) * | 2008-01-04 | 2016-09-29 | Intellikine Llc | Certain Chemical Entities, Compositions And Methods |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| WO2009114870A2 (en) * | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Kinase inhibitors and methods of use |
| WO2009114874A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
| MX2011000216A (es) * | 2008-07-08 | 2011-03-29 | Intellikine Inc | Inhibidores de cinasa y metodos para su uso. |
| WO2010006072A2 (en) | 2008-07-08 | 2010-01-14 | The Regents Of The University Of California | Mtor modulators and uses thereof |
| CA2738429C (en) | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| CA2740885C (en) | 2008-10-16 | 2018-04-03 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
| US8476282B2 (en) * | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
| US8592431B2 (en) | 2009-01-30 | 2013-11-26 | Takeda Pharmaceutical Company Limited | Fused ring compound and use thereof |
| WO2010129816A2 (en) | 2009-05-07 | 2010-11-11 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
| US8980899B2 (en) | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
| AU2011255218B2 (en) | 2010-05-21 | 2015-03-12 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| CA2817577A1 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| TWI659956B (zh) | 2011-01-10 | 2019-05-21 | 美商英菲尼提製藥股份有限公司 | 製備異喹啉酮之方法及異喹啉酮之固體形式 |
| CN103476410B (zh) * | 2011-01-11 | 2020-02-21 | 戴麦里克斯生物科学有限公司 | 联合疗法 |
| TWI592411B (zh) | 2011-02-23 | 2017-07-21 | 英特爾立秦有限責任公司 | 激酶抑制劑之組合及其用途 |
| CN102816126A (zh) * | 2011-06-07 | 2012-12-12 | 中国药科大学 | 具有心血管活性的胺磺酰芳基取代的三氮唑类衍生物、其制备方法及用途 |
| JP6027610B2 (ja) | 2011-07-19 | 2016-11-16 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 複素環式化合物及びその使用 |
| HK1198475A1 (en) | 2011-07-19 | 2015-05-08 | 无限药品股份有限公司 | Heterocyclic compounds and uses thereof |
| AR091790A1 (es) | 2011-08-29 | 2015-03-04 | Infinity Pharmaceuticals Inc | Derivados de isoquinolin-1-ona y sus usos |
| MX370814B (es) | 2011-09-02 | 2020-01-08 | Univ California | Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas. |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| SG11201502331RA (en) | 2012-09-26 | 2015-04-29 | Univ California | Modulation of ire1 |
| NZ744567A (en) | 2012-11-01 | 2020-03-27 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| TWI657085B (zh) | 2013-10-04 | 2019-04-21 | 英菲尼提製藥股份有限公司 | 雜環化合物及其用途 |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| NZ724368A (en) | 2014-03-19 | 2023-07-28 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US10350223B2 (en) | 2015-03-03 | 2019-07-16 | Richard W. Yee | Compositions and methods for treating ocular diseases |
| US10160761B2 (en) | 2015-09-14 | 2018-12-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| UA125216C2 (uk) | 2016-06-24 | 2022-02-02 | Інфініті Фармасьютікалз, Інк. | Комбінована терапія |
| AR108906A1 (es) | 2016-06-29 | 2018-10-10 | Bristol Myers Squibb Co | Heterociclos de biarilmetilo |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3257390A (en) * | 1963-06-12 | 1966-06-21 | Merck & Co Inc | Ring a unsaturated 21-hydroxy-3-oxo-17alpha-pregnane-17-carboxylic acid lactone diuretic agents |
| DE2652761C2 (de) * | 1976-11-16 | 1985-11-21 | Schering AG, 1000 Berlin und 4709 Bergkamen | 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
| DE3506100A1 (de) * | 1985-02-18 | 1986-08-21 | Schering AG, 1000 Berlin und 4709 Bergkamen | 1(alpha).7(alpha)-dithiosubstituierte spirolactone, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| CA2075627A1 (en) * | 1990-02-13 | 1991-08-14 | William J. Greenlee | Angiotensin ii antagonists incorporating a substituted benzyl element |
| WO1991015206A1 (en) * | 1990-04-05 | 1991-10-17 | E.I. Du Pont De Nemours And Company | Treatment of glaucoma and ocular hypertension with imidazole angiotensin-ii receptor antagonists |
| CA2053148A1 (en) * | 1990-10-16 | 1992-04-17 | Karnail Atwal | Dihydropyrimidine derivatives |
| US5049565A (en) * | 1990-12-07 | 1991-09-17 | Merck & Co., Inc. | Microbial transformation process for preparing anti-hypertensive products |
| WO1992020662A1 (en) * | 1991-05-10 | 1992-11-26 | Merck & Co., Inc. | Acidic aralkyl triazole derivatives active as angiotensin ii antagonists |
| US5529992A (en) * | 1992-04-21 | 1996-06-25 | Curators Of The University Of Missouri | Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors |
| US5264447A (en) * | 1992-09-01 | 1993-11-23 | Merck & Co., Inc. | Angiotensin II antagonist |
| WO1994009778A1 (en) * | 1992-10-26 | 1994-05-11 | Merck & Co., Inc. | Combinations of angiotensin-ii receptor antagonists and diuretics |
| CA2125251C (en) * | 1993-06-07 | 2005-04-26 | Yoshiyuki Inada | A pharmaceutical composition for angiotensin ii-mediated diseases |
-
1996
- 1996-06-05 DE DE69620756T patent/DE69620756T2/de not_active Expired - Fee Related
- 1996-06-05 AU AU61580/96A patent/AU6158096A/en not_active Abandoned
- 1996-06-05 WO PCT/US1996/009342 patent/WO1996040258A2/en not_active Application Discontinuation
- 1996-06-05 JP JP9501683A patent/JPH11509838A/ja not_active Abandoned
- 1996-06-05 PT PT96919173T patent/PT831911E/pt unknown
- 1996-06-05 CZ CZ19973848A patent/CZ291268B6/cs not_active IP Right Cessation
- 1996-06-05 EP EP96919173A patent/EP0831911B1/en not_active Expired - Lifetime
- 1996-06-05 DK DK96919173T patent/DK0831911T3/da active
- 1996-06-05 CA CA002224222A patent/CA2224222A1/en not_active Abandoned
- 1996-06-05 KR KR1019970709165A patent/KR19990022723A/ko not_active Ceased
- 1996-06-05 IL IL12224696A patent/IL122246A/en not_active IP Right Cessation
- 1996-06-05 BR BR9608505A patent/BR9608505A/pt not_active Application Discontinuation
- 1996-06-05 ES ES96919173T patent/ES2175098T3/es not_active Expired - Lifetime
- 1996-06-05 CN CN96196086A patent/CN1192696A/zh active Pending
- 1996-06-05 AT AT96919173T patent/ATE216261T1/de not_active IP Right Cessation
-
2002
- 2002-10-15 US US10/271,362 patent/US20040102423A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2175098T3 (es) | 2002-11-16 |
| CZ291268B6 (cs) | 2003-01-15 |
| IL122246A0 (en) | 1998-04-05 |
| WO1996040258A2 (en) | 1996-12-19 |
| WO1996040258A3 (en) | 1997-01-23 |
| JPH11509838A (ja) | 1999-08-31 |
| US20040102423A1 (en) | 2004-05-27 |
| IL122246A (en) | 2004-06-01 |
| ATE216261T1 (de) | 2002-05-15 |
| EP0831911A2 (en) | 1998-04-01 |
| EP0831911B1 (en) | 2002-04-17 |
| DK0831911T3 (da) | 2002-07-22 |
| CZ384897A3 (cs) | 1998-05-13 |
| CN1192696A (zh) | 1998-09-09 |
| DE69620756D1 (de) | 2002-05-23 |
| DE69620756T2 (de) | 2002-11-14 |
| CA2224222A1 (en) | 1996-12-19 |
| BR9608505A (pt) | 1999-07-06 |
| AU6158096A (en) | 1996-12-30 |
| KR19990022723A (ko) | 1999-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT831911E (pt) | Terapeutica de combinacao de espironolactona e antagonista da angiotensina ii para o tratamento de insuficiencia cardiaca congestiva | |
| WO1996040255A3 (en) | Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist | |
| NZ310730A (en) | Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of congestive heart failure | |
| DE69007740D1 (de) | Substituierte 5-[(Tetrazolyl)alkenyl]-Imidazole. | |
| IE902139L (en) | Imidazolyl alkenoic acids | |
| MY110205A (en) | Imidazolyl-alkenoic acids. | |
| IE902140L (en) | Imidazolyl alkenoic acids | |
| NO872863L (no) | Analogifremgangsmte for fremstilling av terapeutiske imidazoler som blokkerer angiotensin-ii-reseptorer. | |
| EP0437103A3 (en) | Substituted 5-(alkyl)carboxamide imidazoles | |
| RU94018226A (ru) | Метансульфонат (е)-3-/2-н-бутил-1-//4-карбоксифенил/метил/-1н-имидазол-5-ил/-2-/2-тиенил/метил-2-пропеновой кислоты, способ его получения, фармацевтическая композиция на его основе | |
| NZ330889A (en) | Cycloalkyl substituted imidazoles and their use in treating CSB/RK/p38 kinase mediated diseases | |
| CA2110806A1 (en) | 4-(1h-pyrrol-1-yl)imidazoles with angiotensin ii antagonist activity | |
| WO2002009760A3 (en) | Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure | |
| AU641952B2 (en) | Substituted N-(imidazolyl)alkyl alanine derivatives | |
| ZA924954B (en) | New triazolopyrimidine derivatives which are angiotensin ii receptor antagonists;processes or preparing them and pharmaceutical compositions containing them | |
| EP0726072A3 (en) | Composition for the treatment of hypertension and congestive heart failure, containing an angiotensin II antagonist and an endopeptidase inhibitor | |
| WO1992020651A3 (en) | N-(heteroaryl)-imidazolyl-alkenoic acids | |
| AU3635793A (en) | Pyrazolopyrimidin derivatives as angiotensin II receptor antagonists | |
| MX9709976A (es) | Terapia de combinacion con espironolactona y antagonista de angiotensina ii para el tratamiento de fallas cardiacas congestivas. | |
| MX9709978A (es) | Terapia de combinacion de antagonista de aldosterona epoxi-esteroidal y antagonista de angiotensina ii para tratamiento de insuficiencia cardiaca congestiva. |